Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck delays Zocor/niacin combo

Executive Summary

Merck will not file its fixed-dose combo drug MK-0524B, combining Zocor (simvastatin) and MK-0524A (extended-release niacin and a flushing inhibitor), in 2007 as planned due to formulation problems, the company announces Sept. 29. The company will continue its late-stage clinical program to support the regulatory filing for the LDL-lowering/HDL-raising triple combination, but it did not announce a new timeline for NDA submission. The firm still expects to file MK-0524A in 2007. Merck has continuously said that neither product will affect Vytorin (simvastatin/ezetimibe), which it co-markets with Schering-Plough (1"The Pink Sheet" Jan. 16, 2006, p. 12)...

You may also be interested in...

Merck agent reduces niacin flushing

Data on Merck's MK-0524, an investigational DP1-receptor antagonist, shows a reduction in flushing in dyslipidemia patients on extended-release niacin. In data presented Nov. 16 at the American Heart Association's Scientific Sessions in Chicago, 37% of patients taking MK-0524 plus niacin reported flushing compared to 61% of patients treated with niacin alone. Merck is in clinical trials for MK-0524a, a fixed-dose combination of niacin and MK-0524 (1"The Pink Sheet" Oct. 2, 2006, In Brief)...

Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck

Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts